Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13886433 | 0.80 | ALDH1A1 (0.54) | HRH3ALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL22388178 | 0.77 | KDM4E (0.39) | HRH3KDM4EALDH1A1CYP3A4TSHR | |
| SCHEMBL22030471 | 0.77 | HRH3 (0.38) | HRH3ALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL8080450 | 0.77 | HTT (0.41) | KDM4ETSHRAOC3 | |
| SCHEMBL27056901 | 0.76 | KDM4E (0.47) | HRH3KDM4EALDH1A1CYP3A4TSHR | |
| SCHEMBL12951070 | 0.75 | HRH3 (0.34) | HRH3 | |
| SCHEMBL126012 | 0.74 | ALDH1A1 (0.44) | ALDH1A1CYP3A4TSHRMAPK1TDP1 | |
| SCHEMBL18364998 | 0.74 | ALDH1A1 (0.39) | HRH3ALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL582268 | 0.73 | KCNH2 (0.42) | TSHRAOC3KCNH2LMNA | |
| SCHEMBL22139579 | 0.72 | ESR1 (0.50) | HRH3ALDH1A1CYP3A4TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209702-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209702-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | HRH3 2998/4885KDM4E 4292/4885ALDH1A1 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.